Tazobactam/piperacillinが有効であったESBL産生大腸菌による急性腎う腎炎の1症例

DOI

書誌事項

タイトル別名
  • A case of acute pyelonephritis caused by extended-spectrum .BETA.-lactamase (ESBL) producing Escherichia coli eliminated by tazobactam/piperacillin

抄録

A 63-year-old man with a history of severe acute pyelonephritis due to extended-spectrum β-lactamase (ESBL) producing isolate was admitted hospital July 30, 2002, with blunt thoracic injury. His history and family history were unremarkable. He underwent indwelling thoracic tube drainage for hemopneumothorax, and epidural intubation for a rib fracture pain. He was given cefazolin for antimicrobial prophylaxis. On hospital day 12, he had a temperature of 38.8°C after urinary catheter insertion. He developed a persistent fever with chills. Escherichia coli were isolated in cultures of blood and urine specimens on August 14, 2002. The result of antibiotic susceptibility against isolates predicted the presence of ESBL producing strain. He was Immediately treated for 6 days with tazobactam/piperacillin (TAZ/PIPC) (0.3g/2g×2/day) iunder a diagnosis of acute pyelonephritis. TAZ/PIPC was effective, but 7 days after treatment was stopped, he underwent a relapse. He was treated for 10 days again. With TAZ/PIPC, resolved the urinary tract infection. He was discharged September 18, 2002. The results of PCR and Sequence showed that ESBL was UOE-2 (CT-XM-14). Results of DNA restriction fragment length polymorphism by pulse fi eld gel electrophoresis showed that the 2 isolates, one from the first infection, and the other from the relapse, were the same clone. TAZ/PIPC is effective for treating urinary tract infections with ESBL producing E. coli. The occurrence of infections caused by ESBL-producing strains thus require consideration in such cases.

収録刊行物

詳細情報 詳細情報について

  • CRID
    1390282681263025664
  • NII論文ID
    130004298172
  • DOI
    10.11250/chemotherapy1995.51.347
  • ISSN
    18845886
    13407007
  • 本文言語コード
    ja
  • データソース種別
    • JaLC
    • CiNii Articles
  • 抄録ライセンスフラグ
    使用不可

問題の指摘

ページトップへ